Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 18/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359303 | 1.00 | OGA (0.46) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL24862858 | 1.00 | OGA (0.46) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21370313 | 0.94 | OGA (0.53) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL28568842 | 0.94 | OGA (0.53) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21369465 | 0.91 | OGA (0.37) | OGAOPRK1 | |
| SCHEMBL28569974 | 0.91 | OGA (0.37) | OGAOPRK1 | |
| SCHEMBL21359511 | 0.91 | OGA (0.42) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL25627777 | 0.87 | OGA (0.33) | OGAOPRK1 | |
| SCHEMBL21370067 | 0.87 | OGA (0.33) | OGAOPRK1 | |
| SCHEMBL22964758 | 0.85 | OGA (0.43) | OGAOPRK1ADRA2BSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118955490-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2021-02-11 | — | — | US | disclosed |
| CN-112218863-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranosidase inhibitors | 比奥根MA公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST3GAL3, ST6GAL1 | OGA 26/4885OPRK1 2094/4885ADRA2B 817/4885 |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST6GAL1, ST3GAL3 | OGA 32/4885OPRK1 2112/4885ADRA2B 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.